$WLSS
Welsis Corp.

2022 Q3 Form 10-K Financial Statement

#000168316822008108 Filed on November 30, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 2021 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.00K $40.00K
YoY Change -33.33%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $20.00K $42.79K
YoY Change -24.81%
Operating Profit -$42.79K
YoY Change -24.81%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$20.00K -$40.00K
YoY Change -33.33%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.00K -$42.79K -$56.90K
YoY Change -64.85% -24.81%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 2.753M shares 2.140M shares
Diluted Shares Outstanding 2.140M shares

Balance Sheet

Concept 2022 Q3 2022 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $18.70K $0.00
Short-Term Investments
Other Short-Term Assets $20.00K $20.00K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $18.70K $20.00K $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $31.33K $39.33K
YoY Change -20.34%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $31.33K $30.00K $39.33K
YoY Change -20.34% -25.0%
TOTAL ASSETS
Total Short-Term Assets $18.70K $20.00K $0.00
Total Long-Term Assets $31.33K $30.00K $39.33K
Total Assets $50.04K $50.00K $39.33K
YoY Change 27.21% 25.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $68.30K $80.00K $55.60K
YoY Change 22.84% 33.33%
Accrued Expenses $0.00 $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $86.94K $90.00K $56.03K
YoY Change 55.16% 50.0%
LONG-TERM LIABILITIES
Long-Term Debt $40.00K $40.00K
YoY Change 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $40.00K $40.00K $40.00K
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $86.94K $90.00K $56.03K
Total Long-Term Liabilities $40.00K $40.00K $40.00K
Total Liabilities $126.9K $130.0K $96.03K
YoY Change 32.18% 30.0%
SHAREHOLDERS EQUITY
Retained Earnings -$99.69K -$56.90K
YoY Change 75.2%
Common Stock $276.00 $200.00
YoY Change 38.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$76.91K -$80.00K -$56.70K
YoY Change
Total Liabilities & Shareholders Equity $50.04K $50.00K $39.33K
YoY Change 27.21% 25.0%

Cashflow Statement

Concept 2022 Q3 2022 2021 Q3
OPERATING ACTIVITIES
Net Income -$20.00K -$42.79K -$56.90K
YoY Change -64.85% -24.81%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$20.00K -$38.79K
YoY Change -31.43%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$30.00K -$30.00K
YoY Change -25.0%
Cash From Investing Activities -$30.00K -$31.33K
YoY Change -20.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $22.58K
YoY Change 11190.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K $88.83K
YoY Change -7.38%
NET CHANGE
Cash From Operating Activities -20.00K -$38.79K
Cash From Investing Activities -30.00K -$31.33K
Cash From Financing Activities 70.00K $88.83K
Net Change In Cash 20.00K $18.70K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$20.00K -$38.79K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Belgrade
CY2022 dei Entity Address Country
EntityAddressCountry
RS
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11070
CY2022 dei Country Region
CountryRegion
1
CY2022 dei City Area Code
CityAreaCode
385
CY2022 dei Local Phone Number
LocalPhoneNumber
5009709
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Public Float
EntityPublicFloat
0 usd
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2752667 shares
CY2022 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001887912
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
usd
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
usd
CY2022Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
usd
CY2021Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
333-261614
CY2022 dei Entity Registrant Name
EntityRegistrantName
WELSIS CORP.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1620699
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
Bulevar Mihajla Pupina 115
CY2022 dei Auditor Firm
AuditorFirmId
5041
CY2022 dei Auditor Location
AuditorLocation
Lakewood, CO
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
18703 usd
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
18703 usd
CY2021Q3 us-gaap Assets Current
AssetsCurrent
0 usd
CY2022Q3 NONE Mobile Application And Website Development
MobileApplicationAndWebsiteDevelopment
31333 usd
CY2021Q3 NONE Mobile Application And Website Development
MobileApplicationAndWebsiteDevelopment
39334 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
31333 usd
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
39334 usd
CY2022Q3 us-gaap Assets
Assets
50036 usd
CY2021Q3 us-gaap Assets
Assets
39334 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
68300 usd
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
55600 usd
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
4329 usd
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
333 usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
14312 usd
CY2021Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
100 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
86941 usd
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
56033 usd
CY2022Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
40000 usd
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
40000 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
40000 usd
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
40000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
126941 usd
CY2021Q3 us-gaap Liabilities
Liabilities
96033 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2752667 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2752667 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2000000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
276 usd
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
200 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22504 usd
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99685 usd
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56899 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-76905 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-56699 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50036 usd
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39334 usd
CY2022 us-gaap Revenues
Revenues
0 usd
CY2021 us-gaap Revenues
Revenues
0 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42785 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56899 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
42785 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
56899 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-42785 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-56899 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42785 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-56899 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2140278 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2140278 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2000000 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2000000 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
0 usd
CY2021Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
200 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-56899 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-56699 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22580 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42785 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-76905 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42785 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-56899 usd
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3996 usd
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
333 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38789 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56566 usd
CY2022 us-gaap Increase Decrease In Intangible Assets Current
IncreaseDecreaseInIntangibleAssetsCurrent
31333 usd
CY2021 us-gaap Increase Decrease In Intangible Assets Current
IncreaseDecreaseInIntangibleAssetsCurrent
39334 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31333 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39334 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22580 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
200 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
14212 usd
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
100 usd
CY2022 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
12700 usd
CY2021 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
55600 usd
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
39333 usd
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
40000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88825 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95900 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
18703 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18703 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
40000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99685 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_843_eus-gaap--UseOfEstimates_zJizMi2KghFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zpUQQKTPfRAb">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2752667 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2752667 shares
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
39333 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
40000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-8000 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-666 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
31333 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
39334 usd
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
7200 usd
CY2021Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
600 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-20934 usd
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11949 usd
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
20934 usd
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
11949 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8985 usd
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11949 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8985 usd
CY2021Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11949 usd
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd

Files In Submission

Name View Source Status
0001683168-22-008108-index-headers.html Edgar Link pending
0001683168-22-008108-index.html Edgar Link pending
0001683168-22-008108.txt Edgar Link pending
0001683168-22-008108-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
none-20220930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
welsis_ex3101.htm Edgar Link pending
welsis_ex3201.htm Edgar Link pending
welsis_i10k-093022.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
none-20220930_cal.xml Edgar Link unprocessable
none-20220930_lab.xml Edgar Link unprocessable
none-20220930_pre.xml Edgar Link unprocessable
none-20220930_def.xml Edgar Link unprocessable
welsis_i10k-093022_htm.xml Edgar Link completed